Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Biochem Pharmacol ; 188: 114520, 2021 06.
Article in English | MEDLINE | ID: mdl-33741328

ABSTRACT

Abnormal outgrowth of sensory nerves is one of the important contributors to pain associated with cancer and its treatments. Primary neuronal cultures derived from dorsal root ganglia (DRG) have been widely used to study pain-associated signal transduction and electrical activity of sensory nerves. However, there are only a few studies using primary DRG neuronal culture to investigate neurite outgrowth alterations due to underlying cancer-related factors and chemotherapeutic agents. In this study, primary DRG sensory neurons derived from mouse, non-human primate, and human were established in serum and growth factor-free conditions. A bovine serum albumin gradient centrifugation method improved the separation of sensory neurons from satellite cells. The purified DRG neurons were able to maintain their heterogeneous subpopulations, and displayed an increase in neurite growth when exposed to cancer-derived conditioned medium, while they showed a reduction in neurite length when treated with a neurotoxic chemotherapeutic agent. Additionally, a semi-automated quantification method was developed to measure neurite length in an accurate and time-efficient manner. Finally, these exogenous factors altered the gene expression patterns of murine primary sensory neurons, which are related to nerve growth, and neuro-inflammatory pain and nociceptor development. Together, the primary DRG neuronal culture in combination with a semi-automated quantification method can be a useful tool for further understanding the impact of exogenous factors on the growth of sensory nerve fibers and gene expression changes in sensory neurons.


Subject(s)
Cancer Pain/physiopathology , Neuronal Outgrowth/physiology , Sensory Receptor Cells/physiology , A549 Cells , Adult , Animals , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/therapeutic use , Cancer Pain/drug therapy , Cancer Pain/etiology , Carcinoma, Lewis Lung/complications , Carcinoma, Lewis Lung/drug therapy , Carcinoma, Lewis Lung/physiopathology , Cells, Cultured , Female , Humans , Macaca mulatta , Male , Mice , Mice, Inbred C57BL , Neuronal Outgrowth/drug effects , Paclitaxel/pharmacology , Paclitaxel/therapeutic use , Sensory Receptor Cells/drug effects
2.
Int J Mol Sci ; 21(21)2020 Oct 22.
Article in English | MEDLINE | ID: mdl-33105841

ABSTRACT

It is established that cancer cachexia causes limb muscle atrophy and is strongly associated with morbidity and mortality; less is known about how the development of cachexia impacts the diaphragm. The purpose of this study was to investigate cellular signaling mechanisms related to mitochondrial function, reactive oxygen species (ROS) production, and protein synthesis during the development of cancer cachexia. C57BL/J6 mice developed Lewis Lung Carcinoma for either 0 weeks (Control), 1 week, 2 weeks, 3 weeks, or 4 weeks. At designated time points, diaphragms were harvested and analyzed. Mitochondrial respiratory control ratio was ~50% lower in experimental groups, which was significant by 2 weeks of cancer development, with no difference in mitochondrial content markers COXIV or VDAC. Compared to the controls, ROS was 4-fold elevated in 2-week animals but then was not different at later time points. Only one antioxidant protein, GPX3, was altered by cancer development (~70% lower in experimental groups). Protein synthesis, measured by a fractional synthesis rate, appeared to become progressively lower with the cancer duration, but the mean difference was not significant. The development and progression of cancer cachexia induces marked alterations to mitochondrial function and ROS production in the diaphragm and may contribute to increased cachexia-associated morbidity and mortality.


Subject(s)
Cachexia/metabolism , Carcinoma, Lewis Lung/metabolism , Diaphragm/physiopathology , Mitochondria, Muscle/metabolism , Animals , Antioxidants/metabolism , Cachexia/etiology , Carcinoma, Lewis Lung/physiopathology , Diaphragm/metabolism , Forkhead Box Protein O3/metabolism , Glutathione Peroxidase/metabolism , Male , Mice, Inbred C57BL , Muscle Proteins/metabolism , Reactive Oxygen Species/metabolism , Signal Transduction
3.
Psychoneuroendocrinology ; 122: 104874, 2020 12.
Article in English | MEDLINE | ID: mdl-32979744

ABSTRACT

Cancer-related fatigue at the time of tumor diagnosis is commonly attributed to inflammation associated with the disease process. However, we have previously demonstrated that running wheel deficits occur well before increased expression of proinflammatory cytokines in the liver and brain in a murine model of human papilloma virus-related head and neck cancer (mEER). Further, we have demonstrated that genetic deletion of type I interleukin-1 receptor and MyD88 has no effect. In the current investigation we sought to test the generality of this finding by assessing whether there is a role for toll-like receptor (TLR) 4-dependent inflammation in the fatigue-like behavior observed in mice with Lewis Lung Carcinoma (LLC) or mEER tumors. Genetic deletion of TLR4 attenuated tumor-induced elevations in liver pro-inflammatory cytokine expression in both models. However, it only abrogated wheel running deficits in LLC tumor bearing mice. To determine whether TLR4 signaling in the LLC model involves innate immune cells, mice were treated with the colony stimulating factor (CSF)-1 receptor antagonist PLX-5622 before and throughout tumor development to deplete microglia and peripheral macrophages. Administration of PLX-5622 had no protective effect on wheel running deficits in either mEER or LLC tumor models despite effective depletion of microglia and a down regulation of peripheral proinflammatory cytokine expression. These results indicate that the TLR4 signaling that mediates fatigue-like behavior in LLC mice is not dependent upon microglial or peripheral macrophage activation. Based on the literature and our data demonstrating attenuation of ubiquitin proteasome pathway activation in the gastrocnemius muscle of Tlr4-/- mice implanted with LLC cells, we interpret our current findings as indication that skeletal muscle TLR4 signaling may be involved. These results are important in that they add to the evidence that tumor-induced fatigue develops independently from classical neuroinflammation.


Subject(s)
Carcinoma, Lewis Lung/physiopathology , Fatigue/metabolism , Toll-Like Receptor 4/metabolism , Animals , Carcinoma, Lewis Lung/genetics , Carcinoma, Lewis Lung/metabolism , Cytokines/metabolism , Disease Models, Animal , Fatigue/genetics , Female , Inflammation/metabolism , Macrophage Activation/physiology , Macrophages/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Microglia/metabolism , Signal Transduction/physiology , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/immunology
4.
J Cell Mol Med ; 24(18): 10768-10784, 2020 09.
Article in English | MEDLINE | ID: mdl-32750747

ABSTRACT

Distant metastases occur when non-small cell lung cancer (NSCLC) is at late stages. Bone metastasis is one of the most frequent metastases of NSCLC and leads to poor prognosis. It has been reported that high expression of BMP2 in NSCLC correlates with poor survival, but whether BMP2 contributes to NSCLC bone metastasis remains largely unknown. The activation of BMP signalling is found in metastatic bone tumours of mice Lewis lung carcinoma and predicts poor survival in human NSCLC. BMP2 signalling activation can enhance bone metastasis of Lewis lung carcinoma. Moreover, BMP2 secreted by stroma fibroblasts can promote the migration and invasion of NSCLC cells. Besides, in combination with pre-osteoblast and LLCs, BMP2 could enhance the differentiation of macrophages into osteoclasts to play roles in the osteolytic mechanism of NSCLC bone metastasis. Interestingly, NSCLC cells can also enrich BMP2 to pre-osteoblasts to function in the osteoblastic mechanism. Our results firstly demonstrate the detailed mechanisms about what roles BMP2 signalling play in enhancing NSCLC bone metastases. These findings provide a new potential therapy choice for preventing bone metastases of NSCLC via the inhibition of BMP2 signalling.


Subject(s)
Bone Morphogenetic Protein 2/physiology , Bone Neoplasms/secondary , Carcinoma, Lewis Lung/secondary , Carcinoma, Non-Small-Cell Lung/secondary , Lung Neoplasms/physiopathology , Neoplasm Proteins/physiology , A549 Cells , Animals , Bone Neoplasms/complications , Bone Neoplasms/physiopathology , Carcinoma, Lewis Lung/physiopathology , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/physiopathology , Cell Movement , Female , Fibroblasts/metabolism , Humans , Kaplan-Meier Estimate , Lung Neoplasms/mortality , Mice , Mice, Inbred C57BL , Neoplasm Invasiveness/physiopathology , Osteoblasts/pathology , Osteolysis/etiology , Osteolysis/physiopathology , RAW 264.7 Cells , Signal Transduction , Specific Pathogen-Free Organisms , Stromal Cells/metabolism
5.
J Tradit Chin Med ; 39(4): 559-565, 2019 08.
Article in English | MEDLINE | ID: mdl-32186104

ABSTRACT

OBJECTIVE: To study the anti-tumor effects of the extracts from Huangqi (Radix Astragali Mongolici) and Ezhu (Rhizoma Curcumae Phaeocaulis) on the growth of Lewis lung carcinoma (LLC) in a xenograft mouse model and to investigate the possible underlying mechanism. METHODS: LLC tumor-bearing C57BL/6 mice were treated with normal saline, cisplatin (2 mg/kg intraperitoneally every other day), or Huangqi (Radix Astragali Mongolici) and Ezhu (Rhizoma Curcumae Phaeocaulis) (1∶1, 2∶1, or 3∶1 ratio; 5 , 8 , or 11 g/kg crude drug intragastrically every day) for 15 d. Body weights and tumor volumes were measured every other day. Tumors were excised on day 15 and analyzed. Tumor microvessel density (MVD) was assessed by immunohistochemical staining of CD34; and expression of vascular endothelial cell growth factor (VEGF), the mitogen-activated protein kinases p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinases 1 and 2 (ERK1/2), and Jun N-terminal kinase (JNK) and their phosphorylated forms were assessed by Western blotting. RESULTS: Treatment with cisplatin caused a significant loss of body weight compared with controls, whereas Huangqi (Radix Astragali Mongolici) and Ezhu (Rhizoma Curcumae Phaeocaulis) extract combinations had no effect. Extracts from Huangqi (Radix Astragali Mongolici) and Ezhu (Rhizoma Curcumae Phaeocaulis) significantly decreased tumor weight and tumor MVD compared with controls, and at the 3∶1 treatment group had similar efficacy to cisplatin in reducing MVD. Tumors from Huangqi (Radix Astragali Mongolici) and Ezhu (Rhizoma Curcumae Phaeocaulis) treatments also showed decreased p38 MAPK, p-p38 MAPK, ERK1/2, p-ERK1/2, JNK, and p-JNK expression compared with the control group (all P < 0.01). VEGF protein expression was significantly reduced in the 2∶1 and 3∶1 treatment groups compared with the control group (P < 0.01). CONCLUSION: Extracts from Huangqi (Radix Astragali Mongolici) and Ezhu (Rhizoma Curcumae Phaeocaulis) hindered LLC growth in the xenograft mouse model, possibly via inhibition of the MAPK signaling pathway, VEGF production, and tumor angiogenesis.


Subject(s)
Angiogenesis Inhibitors/administration & dosage , Carcinoma, Lewis Lung/drug therapy , Cell Proliferation/drug effects , Drugs, Chinese Herbal/administration & dosage , Lung Neoplasms/drug therapy , Mitogen-Activated Protein Kinases/metabolism , Vascular Endothelial Growth Factor A/metabolism , Animals , Astragalus propinquus , Carcinoma, Lewis Lung/genetics , Carcinoma, Lewis Lung/metabolism , Carcinoma, Lewis Lung/physiopathology , Drugs, Chinese Herbal/chemistry , Humans , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Lung Neoplasms/physiopathology , Male , Mice , Mice, Inbred C57BL , Mitogen-Activated Protein Kinases/genetics , Neovascularization, Pathologic , Signal Transduction/drug effects , Vascular Endothelial Growth Factor A/genetics
6.
Sci Rep ; 8(1): 14002, 2018 09 18.
Article in English | MEDLINE | ID: mdl-30228362

ABSTRACT

Detection of cold allodynia is a very important aspect in the study of pain behavior. An effective and concise device for detecting cold pain has always been the hope of many researchers. Here, an easily produced and operated cold plate device is presented for the assessment of cold allodynia in mice. The device used to detect cold allodynia has two components: a chamber consists of a cylinder for animal experiment and a cube box around the chamber for holding ice to keep temperature stable. In the testing chamber, a mouse was placed on the circular plexiglass plate steady at 4 °C above ice for five minutes. The tested mouse will lift its paw when exposed to the cold plate. The number of lifts will present animal's response to the degree of cold stimulation. To evaluate this approach, three commonly used pain models of mice were tested: formalin test, bone cancer pain (BCP), and chronic constriction injury (CCI). As is reported in other literatures, these three pain mice models showed increased sensitivity to cold stimulation. The new device is indeed suitable for detecting cold allodynia behavior in mice. Comparisons with existing devices of detecting cold allodynia, such as the cold plate in the market (UGO, Panlab, Columbus, etc.), the new device has the advantages of low cost, simple operation and easy popularization and can detect cold allodynia behavior of mice very well. This is a very practical and economical device to detect cold allodynia behavior.


Subject(s)
Cancer Pain/complications , Carcinoma, Lewis Lung/physiopathology , Cold Temperature , Constriction, Pathologic/complications , Disease Models, Animal , Hyperalgesia/diagnosis , Pain Measurement/instrumentation , Animals , Behavior, Animal , Hyperalgesia/etiology , Male , Mice , Mice, Inbred C57BL , Pain Measurement/methods
7.
J Integr Med ; 16(4): 283-289, 2018 07.
Article in English | MEDLINE | ID: mdl-29752140

ABSTRACT

OBJECTIVE: Escape from the body's immune response is a basic characteristic of lung cancer, and indoleamine-2,3-dioxygenase (IDO) plays a key role in mediating immune escape of non-small-cell lung cancer, which leads to recurrence and metastasis. Feiji Recipe, a compound Chinese herbal medicine, has the effect of stabilizing lesions and prolonging survival in patients with lung cancer. The purpose of this study was to investigate the mechanisms underlying the anticancer properties of Feiji Recipe. METHODS: An orthotopic transplant model of mouse Lewis lung cancer, with stable expression of IDO gene, was established in C57BL/6 mice. Optical imaging was used to observe the effects of Feiji Recipe in the treatment of lung cancer in vivo. The effects of Feiji Recipe on the proliferation of mouse Lewis lung cancer cell line 2LL, 2LL-enhanced green fluorescent protein (2LL-EGFP) and 2LL-EGFP-IDO were investigated, and the apoptosis of T-cells was examined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide using flow cytometry. Chemical composition of Feiji Recipe was validated by high-performance liquid chromatography. RESULTS: Compared to the control group, the survival of animals treated with Feiji Recipe was significantly prolonged (P = 0.0074), and the IDO protein level decreased (P = 0.0072); moreover, the percentages of CD4+CD25+ T-cells and Foxp3+ T-cells were significantly decreased (P < 0.05). The molecular mechanism of Feiji Recipe against lung cancer may relate to the regulation of immune cells, such as T-cells and regulatory T-cells. CONCLUSION: The molecular mechanism of Feiji Recipe in treatment of lung cancer is to restore the function of T-cells in the cancer microenvironment through interfering with the IDO pathway.


Subject(s)
Carcinoma, Lewis Lung/drug therapy , Cell Proliferation/drug effects , Drugs, Chinese Herbal/administration & dosage , Growth Inhibitors/administration & dosage , Indoleamine-Pyrrole 2,3,-Dioxygenase/immunology , Lung Neoplasms/drug therapy , Animals , Apoptosis/drug effects , Carcinoma, Lewis Lung/enzymology , Carcinoma, Lewis Lung/immunology , Carcinoma, Lewis Lung/physiopathology , Disease Models, Animal , Humans , Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics , Lung Neoplasms/enzymology , Lung Neoplasms/immunology , Lung Neoplasms/physiopathology , Male , Mice , Mice, Inbred C57BL , T-Lymphocytes, Regulatory/drug effects , T-Lymphocytes, Regulatory/immunology
8.
Nat Neurosci ; 20(7): 934-942, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28581479

ABSTRACT

Anorexia is a common manifestation of chronic diseases, including cancer. Here we investigate the contribution to cancer anorexia made by calcitonin gene-related peptide (CGRP) neurons in the parabrachial nucleus (PBN) that transmit anorexic signals. We show that CGRPPBN neurons are activated in mice implanted with Lewis lung carcinoma cells. Inactivation of CGRPPBN neurons before tumor implantation prevents anorexia and loss of lean mass, and their inhibition after symptom onset reverses anorexia. CGRPPBN neurons are also activated in Apcmin/+ mice, which develop intestinal cancer and lose weight despite the absence of reduced food intake. Inactivation of CGRPPBN neurons in Apcmin/+ mice permits hyperphagia that counteracts weight loss, revealing a role for these neurons in a 'nonanorexic' cancer model. We also demonstrate that inactivation of CGRPPBN neurons prevents lethargy, anxiety and malaise associated with cancer. These findings establish CGRPPBN neurons as key mediators of cancer-induced appetite suppression and associated behavioral changes.


Subject(s)
Anorexia/physiopathology , Calcitonin Gene-Related Peptide/physiology , Carcinoma, Lewis Lung/physiopathology , Illness Behavior/physiology , Neoplasms/physiopathology , Parabrachial Nucleus/physiology , Adenomatous Polyposis Coli Protein/genetics , Animals , Behavior, Animal/physiology , Body Weight , Cachexia/physiopathology , Calcitonin Gene-Related Peptide/antagonists & inhibitors , Calcitonin Gene-Related Peptide/genetics , Clozapine/analogs & derivatives , Clozapine/pharmacology , Energy Metabolism/physiology , Female , Male , Metalloendopeptidases/pharmacology , Mice , Mice, Transgenic , Parabrachial Nucleus/drug effects , Tetanus Toxin/pharmacology , Tumor Cells, Cultured/transplantation
9.
BMC Complement Altern Med ; 17(1): 210, 2017 Apr 11.
Article in English | MEDLINE | ID: mdl-28399860

ABSTRACT

BACKGROUND: JC-001 is a Chinese medicine that can modulate the immunity in Hepa 1-6 tumor-bearing mice, and we questioned whether JC-001 can serve as efficient adjuvant chemotherapy. We aimed to identify a novel approach for enhancing cis-diamminedichloroplatinum (II) (CDDP)-based chemotherapy by immunomodulation. METHODS: The anti-tumor activity in vitro was determined based on foci formation and a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A LLC1 tumor xenograft model was used to analyze the activity of tumor rejection in vivo. The tumors were analyzed through hematoxylin and eosin (H&E) staining, immunohistochemistry (IHC) staining and cytokine arrays. RESULTS: JC-001 suppressed foci formation and reduced the viability of Lewis lung carcinoma (LLC1) cells in vitro. JC-001 suppressed LLC1 tumor growth in immunodeficient BALB/c nude mice and in immunocompetent C57BL/6 mice to an even greater extent. Furthermore, JC-001 up-regulated interferon-γ expression in the tumor microenvironment, enhanced the Th1 response in tumor-bearing mice, and increased the chemosensitivity of LLC1 tumors to CDDP chemotherapy. The results of our study suggest that JC-001 is associated with low cytotoxicity and can significantly suppress tumor growth by enhancing the Th1 response. CONCLUSION: JC-001 is a Chinese medicine with potential clinical applications in CDDP-based chemotherapeutic regimens.


Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Lewis Lung/drug therapy , Drugs, Chinese Herbal/administration & dosage , Lung Neoplasms/drug therapy , Animals , Apoptosis/drug effects , Carcinoma, Lewis Lung/genetics , Carcinoma, Lewis Lung/metabolism , Carcinoma, Lewis Lung/physiopathology , Cell Line, Tumor , Cisplatin/administration & dosage , Female , Humans , Interferon-gamma/genetics , Interferon-gamma/immunology , Lung Neoplasms/genetics , Lung Neoplasms/immunology , Lung Neoplasms/physiopathology , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Nude
10.
Biochem Biophys Res Commun ; 470(1): 101-106, 2016 Jan 29.
Article in English | MEDLINE | ID: mdl-26766793

ABSTRACT

Tumor-associated macrophages (TAMs) play pivotal roles in the progression of cancer. In order to investigate a novel candidate that inhibits the tumor-supporting M2-like phenotype of TAMs, a murine macrophage cell line RAW 264.7 cells were treated with interleukin (IL)-4. Luteolin inhibited phosphorylation of signal transducer and activator of transcription 6 (STAT6), a main downstream signal of IL-4, and reduced the expression of the M2-associated genes. In addition, Luminex multiplex analysis for secreted cytokines revealed that IL-4-enhanced secretion of chemokine (C-C motif) ligand 2 (CCL2) was reduced by luteolin treatment. IL-4-stimulated migration of monocyte, THP-1 cells, was inhibited by luteolin treatment and recovered by recombinant CCL2 supplement. Moreover, luteolin decreased migration of Lewis lung carcinoma cells in a CCL2-dependent manner. Given the important role of the TAM phenotype in the tumor microenvironment, inhibitory effect of luteolin on the monocyte recruitment and cancer migration via suppression of the TAM-secreted CCL2 may suggest a novel therapeutic approach to treat malignant tumors.


Subject(s)
Carcinoma, Lewis Lung/pathology , Carcinoma, Lewis Lung/physiopathology , Chemokine CCL2/metabolism , Luteolin/administration & dosage , Monocytes/drug effects , Monocytes/physiology , Animals , Cell Movement/drug effects , Dose-Response Relationship, Drug , Mice , Monocytes/cytology , Neoplasm Invasiveness , RAW 264.7 Cells
11.
Zhongguo Zhong Yao Za Zhi ; 41(1): 112-117, 2016 Jan.
Article in Chinese | MEDLINE | ID: mdl-28845651

ABSTRACT

To observe the effect of Epimedii Herba alcohol extract (HE) on tumor growth of lung cancer by establishing the model of Lewis tumor-bearing mice, ELISA method was used to detect the levels of TNF-α, IL-10, IL-17, IL-2 in serum. Ki67 and P53 protein expression was detected in lung cancer tissues by using Western blot assay method and immunohistochemical assay method. The experimental results showed that HE has certain inhibitory effect on Lewis lung cancer tumor growth, and it can reduce the levels of TNF-α, IL-10 and IL-17 in serum, improve the level of IL-2,significantly decrease the expression of Ki67, and significantly increase P53 expression. HE has obvious inhibitory effect against lung cancer, and has the ability to improve immune regulating effect. This study reveals the anti-lung cancer effect of HE may be related to its ability of improving immunity, thus provides the basis for further research on anti-lung cancer effect of HE.


Subject(s)
Carcinoma, Lewis Lung/drug therapy , Cell Proliferation/drug effects , Drugs, Chinese Herbal/administration & dosage , Epimedium/chemistry , Lung Neoplasms/drug therapy , Lung Neoplasms/immunology , Animals , Carcinoma, Lewis Lung/genetics , Carcinoma, Lewis Lung/immunology , Carcinoma, Lewis Lung/physiopathology , Drugs, Chinese Herbal/isolation & purification , Female , Humans , Interleukin-10/genetics , Interleukin-10/immunology , Lung/drug effects , Lung/immunology , Lung Neoplasms/genetics , Mice , Mice, Inbred C57BL , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology
12.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi ; 31(3): 297-301, 2015 Mar.
Article in Chinese | MEDLINE | ID: mdl-25744830

ABSTRACT

OBJECTIVE: To investigate the effect of Tanreqing injection on immune function of mice with Lewis lung carcinoma treated by chemotherapy and discuss the immunoregulatory function of this herb. METHODS: All mouse models with Lewis lung carcinoma were randomly divided to four groups: model control group, Tanreqing injection group, chemotherapy group and chemotherapy combined with Tanreqing injection group (8 rats in each group). Other 8 normal mice served as a normal control group. After treatment, peripheral blood was collected from the mice of all groups before they were sacrificed. Tumor tissue, femur, thymus and spleen were obtained to perform the following experiments. Tumor mass and volume were first observed. The apoptosis levels of tumor cells and the ratios of CD3⁺T lymphocyte and CD3⁻NK1.1⁺ cells in the infiltrating lymphocytes in the tumor tissues were analyzed by flow cytometry. Thymus indexes (TI) were counted, and the structure of thymus was observed using HE staining. Cytotoxicity of spleen cytotoxic T cells (CTL) were investigated by MTT assay. The number of lymphocytes in the periphery blood and the nucleated cells in femur were also detected, and the expression levels of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) mRNA in the tumor tissues were studied by reverse transcription PCR. RESULTS: After chemotherapy, TI, the number of the nucleated cells in femur and lymphocytes in peripheral blood of chemotherapy combined with Tanreqing injection group were obviously higher than those in the chemotherapy group. The ratios of CD3⁺T lymphocytes and CD3⁻NK1.1⁺ cells in the infiltrating lymphocytes in the tumor tissues of chemotherapy combined with Tanreqing injection group were also significantly higher than those in the chemotherapy group. Besides, compared with chemotherapy group, cytotoxicity of CTL in chemotherapy combined with Tanreqing injection group was improved notably. Meanwhile, the expression levels of IFN-γ and TNF-α mRNA in tumor tissues of chemotherapy combined with Tanreqing injection group were dramatically higher than those in chemotherapy group. CONCLUSION: Tanreqing injection has certain protective effects on damaged immune function of body with lung carcinoma induced by chemotherapy, and also improves the anti-tumor immune function of the body.


Subject(s)
Carcinoma, Lewis Lung/drug therapy , Carcinoma, Lewis Lung/immunology , Drugs, Chinese Herbal/administration & dosage , Lung Neoplasms/drug therapy , Lung Neoplasms/immunology , Animals , Apoptosis/drug effects , Carcinoma, Lewis Lung/genetics , Carcinoma, Lewis Lung/physiopathology , Disease Models, Animal , Female , Interferon-gamma/genetics , Interferon-gamma/immunology , Lung Neoplasms/genetics , Lung Neoplasms/physiopathology , Male , Mice , Mice, Inbred C57BL , Spleen/drug effects , Spleen/immunology , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes, Cytotoxic/cytology , T-Lymphocytes, Cytotoxic/drug effects , T-Lymphocytes, Cytotoxic/immunology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology
13.
Genet Mol Res ; 13(4): 10562-73, 2014 Dec 12.
Article in English | MEDLINE | ID: mdl-25511041

ABSTRACT

The renin-angiotensin system (RAS) influences cancer biology and is frequently dysregulated in malignancy. However, regulation of tumor local RAS remains poorly understood. Hypoxia is a hallmark of solid tumors and affects nearly every major aspect of cancer biology. Previous studies have shown that hypoxia can regulate RAS expression in somatic tissues and cells. The aim of this study was to investigate the influence of hypoxia on local RAS expression in mouse Lewis lung carcinoma (LLC) cells. For hypoxia treatment, LLC cells were cultured in a hypoxia incubator or treated with hypoxia-mimetic cobalt chloride. Hypoxia up-regulated angiotensin II, angiotensin-converting enzyme (ACE), and angiotensin II type 1 receptor (AT1R), and down-regulated ACE2 and angiotensin II type 2 receptor in LLC cells. Captopril, an ACE inhibitor, and losartan, an AT1R blocker, decreased expression of ACE and AT1R, but increased expression of ACE2 and angiotensin II type 2 receptor in LLC cells under hypoxia. Captopril and losartan also suppressed vascular endothelial growth factor-A expression in LLC cells under hypoxia. These findings suggest that hypoxia induces dysregulation of local RAS in LLC cells. The pathophysiological importance of hypoxia-induced RAS dysregulation and potentially therapeutic effects of RAS inhibitors on hypoxic tumor cells should be further examined.


Subject(s)
Carcinoma, Lewis Lung/genetics , Cell Hypoxia , Renin-Angiotensin System/genetics , Angiotensin II/biosynthesis , Angiotensin-Converting Enzyme 2 , Animals , Carcinoma, Lewis Lung/physiopathology , Carcinoma, Lewis Lung/therapy , Gene Expression Regulation, Neoplastic , Humans , Peptidyl-Dipeptidase A/biosynthesis , Receptor, Angiotensin, Type 2/biosynthesis
14.
Radiat Res ; 181(3): 272-83, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24568128

ABSTRACT

Proton radiation is touted for improved tumor targeting, over standard gamma radiation, due to the physical advantages of ion beams for radiotherapy. Recent studies from our laboratory demonstrate that in addition to these targeting advantages, proton irradiation can inhibit angiogenic and immune factors critical to "hallmark" processes that impact cancer progression, thereby modulating tumor development. Outside the therapeutic utilization of protons, high-energy protons constitute a principal component of galactic cosmic rays and thus are a consideration in carcinogenesis risk for space flight. Given that proton irradiation modulates fundamental biological processes known to decrease with aging (e.g. angiogenesis and immunogenicity), we investigated how proton irradiation impacts tumor advancement as a function of host age, a question with both therapeutic and carcinogenesis implications. Tumor lag time and growth dynamics were tracked, after injection of murine Lewis lung carcinoma (LLC) cells into syngeneic adolescent (68 day) vs. old (736 day) C57BL/6 mice with or without coincident irradiation. Tumor growth was suppressed in old compared to adolescent mice. These differences were further modulated by proton irradiation (1 GeV), with increased inhibition and a significant radiation-altered molecular fingerprint evident in tumors grown in old mice. Through global transcriptome analysis, TGFß1 and TGFß2 were determined to be key players that contributed to the tumor dynamics observed. These findings suggest that old hosts exhibit a reduced capacity to support tumor advancement, which can be further reduced by proton irradiation.


Subject(s)
Aging , Carcinoma, Lewis Lung/physiopathology , Carcinoma, Lewis Lung/radiotherapy , Disease Progression , Proton Therapy , Aging/radiation effects , Animals , Carcinoma, Lewis Lung/metabolism , Carcinoma, Lewis Lung/pathology , Cell Line, Tumor , Cell Proliferation/radiation effects , Gene Expression Profiling , Mice , Transforming Growth Factor beta1/metabolism , Transforming Growth Factor beta2/metabolism , Tumor Burden/radiation effects
15.
FASEB J ; 27(9): 3572-82, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23733748

ABSTRACT

Cachexia is a wasting condition defined by skeletal muscle atrophy in the setting of systemic inflammation. To explore the site at which inflammatory mediators act to produce atrophy in vivo, we utilized mice with a conditional deletion of the inflammatory adaptor protein myeloid differentiation factor 88 (MyD88). Although whole-body MyD88-knockout (wbMyD88KO) mice resist skeletal muscle atrophy in response to LPS, muscle-specific deletion of MyD88 is not protective. Furthermore, selective reexpression of MyD88 in the muscle of wbMyD88KO mice via electroporation fails to restore atrophy gene induction by LPS. To evaluate the role of glucocorticoids as the inflammation-induced mediator of atrophy in vivo, we generated mice with targeted deletion of the glucocorticoid receptor in muscle (mGRKO mice). Muscle-specific deletion of the glucocorticoid receptor affords a 71% protection against LPS-induced atrophy compared to control animals. Furthermore, mGRKO mice exhibit 77% less skeletal muscle atrophy than control animals in response to tumor growth. These data demonstrate that glucocorticoids are a major determinant of inflammation-induced atrophy in vivo and play a critical role in the pathogenesis of endotoxemic and cancer cachexia.


Subject(s)
Cachexia/etiology , Cachexia/metabolism , Carcinoma, Lewis Lung/physiopathology , Glucocorticoids/metabolism , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscular Atrophy/metabolism , Myeloid Differentiation Factor 88/metabolism , Animals , Blotting, Western , Carcinoma, Lewis Lung/genetics , Carcinoma, Lewis Lung/metabolism , Immunohistochemistry , In Situ Hybridization , Inflammation Mediators/pharmacology , Lipopolysaccharides/pharmacology , Mice , Mice, Knockout , Muscle, Skeletal/drug effects , Muscular Atrophy/chemically induced , Muscular Atrophy/genetics , Myeloid Differentiation Factor 88/genetics , Real-Time Polymerase Chain Reaction , Receptors, Glucocorticoid/genetics , Receptors, Glucocorticoid/metabolism , Signal Transduction/drug effects , Signal Transduction/genetics
16.
J Exp Med ; 208(7): 1351-8, 2011 Jul 04.
Article in English | MEDLINE | ID: mdl-21646395

ABSTRACT

For malignant growth, solid cancers must stimulate the formation of new blood vessels by producing vascular endothelial growth factor (VEGF-A), which is required for the survival of tumor-associated vessels. Novel anticancer agents that block VEGF-A signaling trigger endothelial cell (EC) apoptosis and vascular regression preferentially within tumors, but how the ECs die is not understood. In this study, we demonstrate that VEGF-A deprivation, provoked either by drug-induced tumor shrinkage or direct VEGF-A blockade, up-regulates the proapoptotic BH3 (Bcl-2 homology 3)-only Bcl-2 family member Bim in ECs. Importantly, the tumor growth inhibitory activity of a VEGF-A antagonist required Bim-induced apoptosis of ECs. These findings thus reveal the mechanism by which VEGF-A blockade induces EC apoptosis and impairs tumor growth. They also indicate that drugs mimicking BH3-only proteins may be exploited to kill tumor cells not only directly but also indirectly by ablating the tumor vasculature.


Subject(s)
Apoptosis Regulatory Proteins/physiology , Carcinoma, Lewis Lung/drug therapy , Carcinoma, Lewis Lung/physiopathology , Melanoma, Experimental/drug therapy , Melanoma, Experimental/physiopathology , Membrane Proteins/physiology , Proto-Oncogene Proteins/physiology , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Apoptosis/physiology , Apoptosis Regulatory Proteins/deficiency , Apoptosis Regulatory Proteins/genetics , Bcl-2-Like Protein 11 , Carcinoma, Lewis Lung/blood supply , Carcinoma, Lewis Lung/pathology , Cell Line, Tumor , Endothelial Cells/drug effects , Endothelial Cells/pathology , Endothelial Cells/physiology , Ganciclovir/pharmacology , Gene Expression/drug effects , Melanoma, Experimental/blood supply , Melanoma, Experimental/pathology , Membrane Proteins/deficiency , Membrane Proteins/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic , Proto-Oncogene Proteins/deficiency , Proto-Oncogene Proteins/genetics , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Thymidine Kinase/genetics , Thymidine Kinase/metabolism , Vascular Endothelial Growth Factor A/deficiency , Vascular Endothelial Growth Factor A/genetics
17.
Am J Respir Crit Care Med ; 182(10): 1273-81, 2010 Nov 15.
Article in English | MEDLINE | ID: mdl-20595227

ABSTRACT

RATIONALE: IL-5 is a T helper 2 cytokine important in the trafficking and survival of eosinophils. Because eosinophils can be found in malignant pleural effusions (MPE) from mice and humans, we asked whether IL-5 is involved in the pathogenesis of MPE. OBJECTIVES: To determine the role of IL-5 in MPE formation. METHODS: The effects of IL-5 on experimental MPE induced in C57BL/6 mice by intrapleural injection of syngeneic lung (Lewis lung cancer [LLC]) or colon (MC38) adenocarcinoma cells were determined using wild-type (il5(+/+)) and IL-5-deficient (il5⁻(/)⁻) mice, exogenous administration of recombinant mouse (rm) IL-5, and in vivo antibody-mediated neutralization of endogenous IL-5. The direct effects of rmIL-5 on LLC cell proliferation and gene expression in vitro were determined by substrate reduction and microarray. MEASUREMENTS AND MAIN RESULTS: Eosinophils and IL-5 were present in human and mouse MPE, but the cytokine was not detected in mouse (LLC) or human (A549) lung and mouse colon (MC38) adenocarcinoma-conditioned medium, suggesting production by host cells in MPE. Compared with il5(+/+) mice, il5⁻(/)⁻ mice showed markedly diminished MPE formation in response to both LLC and MC38 cells. Exogenous IL-5 promoted MPE formation in il5(+/+) and il5⁻(/)⁻ mice, whereas anti-IL-5 antibody treatment limited experimental MPE in il5(+/+) mice. Exogenous IL-5 had no effects on LLC cell proliferation and gene expression; however, IL-5 was found to be responsible for recruitment of eosinophils and tumor-promoting myeloid suppressor cells to MPE in vivo. CONCLUSIONS: Host-derived IL-5 promotes experimental MPE and may be involved in the pathogenesis of human MPE.


Subject(s)
Adenocarcinoma/physiopathology , Interleukin-5/physiology , Lung Neoplasms/physiopathology , Pleural Effusion, Malignant/physiopathology , Adenocarcinoma/complications , Animals , Carcinoma, Lewis Lung/complications , Carcinoma, Lewis Lung/physiopathology , Cell Line, Tumor , Dose-Response Relationship, Drug , Eosinophils/physiology , Flow Cytometry , Gene Expression Profiling , Humans , Interleukin-5/analysis , Interleukin-5/biosynthesis , Interleukin-5/pharmacology , Lung Neoplasms/complications , Mice , Mice, Inbred C57BL , Pleural Effusion, Malignant/chemically induced , Pleural Effusion, Malignant/chemistry , Pleural Effusion, Malignant/cytology
18.
Bull Exp Biol Med ; 150(2): 233-6, 2010 Dec.
Article in English, Russian | MEDLINE | ID: mdl-21240381

ABSTRACT

Tissue inhibitor of matrix metalloproteinases type 1, inhibiting the majority of matrix metalloproteinases, can both suppress and stimulate tumor growth. The concentrations and activities of tissue matrix metalloproteinase inhibitor-1 were measured in C57Bl/6 mice during progression and metastasizing of Lewis lung adenocarcinoma. Activities of matrix metalloproteinases in tumor tissue of mice were lower than in liver and lung tissues of intact animals. Serum concentration of tissue inhibitor increased significantly during the development of Lewis lung adenocarcinoma. Macrophage depression (injection of gadolinium chloride associated with a decrease in metastasis number) decreased serum concentration of tissue inhibitor, but it did not attain the control level observed in intact mice. These findings attest to a pleiotropic antitumor effect of tissue matrix metalloproteinase inhibitor-1 reflecting disorders in matrix metalloproteinase regulation during the progress of Lewis lung adenocarcinoma in mice.


Subject(s)
Carcinoma, Lewis Lung/physiopathology , Gene Expression Regulation, Neoplastic/physiology , Matrix Metalloproteinase Inhibitors , Neoplasm Metastasis/physiopathology , Tissue Inhibitor of Metalloproteinase-1/metabolism , Animals , Carcinoma, Lewis Lung/metabolism , Gadolinium , Liver/metabolism , Lung/metabolism , Mice , Mice, Inbred C57BL , Tissue Inhibitor of Metalloproteinase-1/blood
19.
Blood ; 114(19): 4310-9, 2009 Nov 05.
Article in English | MEDLINE | ID: mdl-19717647

ABSTRACT

Adult bone marrow (BM) contributes to neovascularization in some but not all settings, and reasons for these discordant results have remained unexplored. We conducted novel comparative studies in which multiple neovascularization models were established in single mice to reduce variations in experimental methodology. In different combinations, BM contribution was detected in ischemic retinas and, to a lesser extent, Lewis lung carcinoma cells, whereas B16 melanomas showed little to no BM contribution. Using this spectrum of BM contribution, we demonstrate the necessity for site-specific expression of stromal-derived factor-1alpha (SDF-1alpha) and its mobilizing effects on BM. Blocking SDF-1alpha activity with neutralizing antibodies abrogated BM-derived neovascularization in lung cancer and retinopathy. Furthermore, secondary transplantation of single hematopoietic stem cells (HSCs) showed that HSCs are a long-term source of neovasculogenesis and that CD133(+)CXCR4(+) myeloid progenitor cells directly participate in new blood vessel formation in response to SDF-1alpha. The varied BM contribution seen in different model systems is suggestive of redundant mechanisms governing postnatal neovasculogenesis and provides an explanation for contradictory results observed in the field.


Subject(s)
Chemokine CXCL12/physiology , Hematopoietic Stem Cells/physiology , Neovascularization, Pathologic , Neovascularization, Physiologic , Animals , Bone Marrow Cells/cytology , Bone Marrow Cells/physiology , Carcinoma, Lewis Lung/blood supply , Carcinoma, Lewis Lung/physiopathology , Chemokine CXCL12/antagonists & inhibitors , Hematopoietic Stem Cells/cytology , Ischemia/pathology , Ischemia/physiopathology , Melanoma, Experimental/blood supply , Melanoma, Experimental/physiopathology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Models, Biological , Receptors, CXCR4/antagonists & inhibitors , Receptors, CXCR4/physiology , Retinal Vessels/pathology
20.
Zhongguo Zhong Yao Za Zhi ; 34(12): 1570-3, 2009 Jun.
Article in Chinese | MEDLINE | ID: mdl-19777849

ABSTRACT

OBJECTIVE: To observe the effect of anti-tumor and mechanism of the extract of Spatholobus suberctus (SSCE) in vivo. METHOD: The mouse model of Lewis lung carcinoma was used to investigate the effects of SSCE on tumor growth and metastasis. Furthermore, we explored the mechanism of anti-tumor by analyze the cell cycle and determine the apoptosis. RESULT: The studies demonstrated that the tumor inhibitory rate of SSCE in low dose group was the highest (30.65%) on Lewis lung cancer. SSCE can resist metastasis, at the same time, it can induce cell cycle arrested in G1 phase, whereas, there was no significant difference in apoptotic rate each group. CONCLUSION: We verified that SSCE exits anti-tumor effect and resist metastasis, furthermore, it can arrest function cell in G1 phase.


Subject(s)
Antineoplastic Agents/pharmacology , Fabaceae/chemistry , Plant Extracts/pharmacology , Animals , Antineoplastic Agents/therapeutic use , Carcinoma, Lewis Lung/drug therapy , Carcinoma, Lewis Lung/physiopathology , Cell Cycle/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Disease Models, Animal , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/physiopathology , Male , Mice , Mice, Inbred C57BL , Plant Extracts/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...